Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675126 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03675126 is a Phase 1 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT03675126, a Phase 1 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.
Interventions
- DRUG SRP-5051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2021-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03675126
The ClinicalTrials.gov registry entry for NCT03675126 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SRP-5051 is the first listed.
NCT03675126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03675126 about?
NCT03675126 is a clinical study titled "An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)". The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.
What is the current status of trial NCT03675126?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-12-19. Estimated completion is 2021-08-25.
What interventions are being tested in trial NCT03675126?
The interventions under investigation include: SRP-5051 (DRUG).
Who is sponsoring clinical trial NCT03675126?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.